SLAM BioTherapeutics
Slam Bio is a biotech company developing a platform of first-in-class monoclonal antibody therapies and antibody-drug conjugates (ADCs) targeting cancer. SLAM Bio’s lead assets demonstrate a profound effect on the tumor microenvironment in preclinical models.
Our Mission
Our mission is to pioneer paradigm-changing therapies that offer a beacon of hope to patients, ushering in a new era of breakthroughs in the fight against cancer.
Our Team
Our seasoned and proven leadership team—led by CEO Steve Potts; Chairman and Co-Founder, Rick Heinick; SAB Chair and Co-Founder, Dr. Steven Rosen; along with an experienced oncology team—has been involved in multiple successful drug development programs and exits. The team includes scientists, clinicians and business professionals, all who bring unique skills and perspectives.
Our Science
Innovation is at the heart of what we do at SLAM Bio.
Our primary indication is acute myeloid leukemia (AML) along with related AML diseases such as myelodysplastic syndrome (MDS). Our secondary indications include myelofibrosis (MF) and cutaneous T-cell lymphoma (CTCL).
Our antibodies target the signaling lymphocytic activation molecule (SLAM) family of receptors, expressed on immune cells that act as master regulators of immune cells. These antibodies exhibit promising capabilities in the modulation of myeloid-derived suppressor cells, B regulatory and T regulatory cells, and the associated activation of cytotoxic T and natural killer cells. We have demonstrated efficacy and tumor microenvironment modulation in a broad spectrum of blood cancers.
The lead antibodies target SLAMF5, which is a survival receptor highly expressed on hematologic malignant cells as well as on immune suppressor cells in the tumor microenvironment. Preclinical data on our lead humanized antibody demonstrates high affinity and strong efficacy.
We have a broad IP portfolio of more than 15 antibodies. Our Phase I will be intiated in 2025 for hematologic cancers.
Our Partners
We have partnered with two leading cancer research institutions, City of Hope and the Weizmann Institute, to develop innovative solutions with the potential to extend and enhance the lives of people with cancer.